Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients

G. Derosa, P. Maffioli, I. Ferrari, R. Mereu, P. D. Ragonesi, F. Querci, I. G. Franzetti, G. Gadaleta, L. Ciccarelli, M. N. Piccinni, A. Dangelo, S. A T Salvadeo

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM). 168 patients with T2DM were randomized to take either pioglitazone 30mg once a day plus vildagliptin 50mg twice a day or glimepiride 2mg 3 times a day plus vildagliptin 50mg twice a day. We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment -cell function index (HOMA-), fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), adiponectin (ADN), resistin (R), tumor necrosis factor- (TNF-), and high sensitivity C-reactive protein (Hs-CRP) at their baseline values, and after 3, 6, 9, and 12 months of treatment. We observed a similar improvement of HbA1c, FPG, PPG, and Hs-CRP compared to baseline in the 2 groups. Fasting plasma insulin, FPPr, Pr/FPI ratio, R, and TNF- were significantly decreased and ADN was significantly increased with pioglitazone plus vildagliptin, but not with glimepiride plus vildagliptin. HOMA-IR, and HOMA- values obtained with pioglitazone plus vildagliptin were significantly better than the values obtained with glimepiride plus vildagliptin. Pioglitazone plus vildagliptin were found to be more effective in preserving -cell function, and in reducing insulin resistance, and inflammatory state parameters.

Original languageEnglish
Pages (from-to)663-669
Number of pages7
JournalHormone and Metabolic Research
Volume42
Issue number9
DOIs
Publication statusPublished - 2010

Fingerprint

pioglitazone
glimepiride
Fasting
Plasmas
Insulin
Proinsulin
Insulin Resistance
Therapeutics
Glucose
Homeostasis
Adiponectin
C-Reactive Protein
Tumor Necrosis Factor-alpha
vildagliptin
Resistin

Keywords

  • -cell
  • glimepiride
  • inflammatory state
  • insulin resistance
  • pioglitazone
  • vildagliptin

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. / Derosa, G.; Maffioli, P.; Ferrari, I.; Mereu, R.; Ragonesi, P. D.; Querci, F.; Franzetti, I. G.; Gadaleta, G.; Ciccarelli, L.; Piccinni, M. N.; Dangelo, A.; Salvadeo, S. A T.

In: Hormone and Metabolic Research, Vol. 42, No. 9, 2010, p. 663-669.

Research output: Contribution to journalArticle

Derosa, G. ; Maffioli, P. ; Ferrari, I. ; Mereu, R. ; Ragonesi, P. D. ; Querci, F. ; Franzetti, I. G. ; Gadaleta, G. ; Ciccarelli, L. ; Piccinni, M. N. ; Dangelo, A. ; Salvadeo, S. A T. / Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients. In: Hormone and Metabolic Research. 2010 ; Vol. 42, No. 9. pp. 663-669.
@article{acb49d587b5047249d262520afc96e09,
title = "Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients",
abstract = "The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM). 168 patients with T2DM were randomized to take either pioglitazone 30mg once a day plus vildagliptin 50mg twice a day or glimepiride 2mg 3 times a day plus vildagliptin 50mg twice a day. We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment -cell function index (HOMA-), fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), adiponectin (ADN), resistin (R), tumor necrosis factor- (TNF-), and high sensitivity C-reactive protein (Hs-CRP) at their baseline values, and after 3, 6, 9, and 12 months of treatment. We observed a similar improvement of HbA1c, FPG, PPG, and Hs-CRP compared to baseline in the 2 groups. Fasting plasma insulin, FPPr, Pr/FPI ratio, R, and TNF- were significantly decreased and ADN was significantly increased with pioglitazone plus vildagliptin, but not with glimepiride plus vildagliptin. HOMA-IR, and HOMA- values obtained with pioglitazone plus vildagliptin were significantly better than the values obtained with glimepiride plus vildagliptin. Pioglitazone plus vildagliptin were found to be more effective in preserving -cell function, and in reducing insulin resistance, and inflammatory state parameters.",
keywords = "-cell, glimepiride, inflammatory state, insulin resistance, pioglitazone, vildagliptin",
author = "G. Derosa and P. Maffioli and I. Ferrari and R. Mereu and Ragonesi, {P. D.} and F. Querci and Franzetti, {I. G.} and G. Gadaleta and L. Ciccarelli and Piccinni, {M. N.} and A. Dangelo and Salvadeo, {S. A T}",
year = "2010",
doi = "10.1055/s-0030-1255036",
language = "English",
volume = "42",
pages = "663--669",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "9",

}

TY - JOUR

T1 - Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients

AU - Derosa, G.

AU - Maffioli, P.

AU - Ferrari, I.

AU - Mereu, R.

AU - Ragonesi, P. D.

AU - Querci, F.

AU - Franzetti, I. G.

AU - Gadaleta, G.

AU - Ciccarelli, L.

AU - Piccinni, M. N.

AU - Dangelo, A.

AU - Salvadeo, S. A T

PY - 2010

Y1 - 2010

N2 - The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM). 168 patients with T2DM were randomized to take either pioglitazone 30mg once a day plus vildagliptin 50mg twice a day or glimepiride 2mg 3 times a day plus vildagliptin 50mg twice a day. We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment -cell function index (HOMA-), fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), adiponectin (ADN), resistin (R), tumor necrosis factor- (TNF-), and high sensitivity C-reactive protein (Hs-CRP) at their baseline values, and after 3, 6, 9, and 12 months of treatment. We observed a similar improvement of HbA1c, FPG, PPG, and Hs-CRP compared to baseline in the 2 groups. Fasting plasma insulin, FPPr, Pr/FPI ratio, R, and TNF- were significantly decreased and ADN was significantly increased with pioglitazone plus vildagliptin, but not with glimepiride plus vildagliptin. HOMA-IR, and HOMA- values obtained with pioglitazone plus vildagliptin were significantly better than the values obtained with glimepiride plus vildagliptin. Pioglitazone plus vildagliptin were found to be more effective in preserving -cell function, and in reducing insulin resistance, and inflammatory state parameters.

AB - The aim of the study was to compare the effects of vildagliptin added to pioglitazone or glimepiride on metabolic and insulin resistance related-indices in poorly controlled type 2 diabetic patients (T2DM). 168 patients with T2DM were randomized to take either pioglitazone 30mg once a day plus vildagliptin 50mg twice a day or glimepiride 2mg 3 times a day plus vildagliptin 50mg twice a day. We evaluated body weight, body mass index (BMI), glycated hemoglobin (HbA1c), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), fasting plasma insulin (FPI), homeostasis model assessment insulin resistance index (HOMA-IR), homeostasis model assessment -cell function index (HOMA-), fasting plasma proinsulin (FPPr), proinsulin/fasting plasma insulin ratio (Pr/FPI ratio), adiponectin (ADN), resistin (R), tumor necrosis factor- (TNF-), and high sensitivity C-reactive protein (Hs-CRP) at their baseline values, and after 3, 6, 9, and 12 months of treatment. We observed a similar improvement of HbA1c, FPG, PPG, and Hs-CRP compared to baseline in the 2 groups. Fasting plasma insulin, FPPr, Pr/FPI ratio, R, and TNF- were significantly decreased and ADN was significantly increased with pioglitazone plus vildagliptin, but not with glimepiride plus vildagliptin. HOMA-IR, and HOMA- values obtained with pioglitazone plus vildagliptin were significantly better than the values obtained with glimepiride plus vildagliptin. Pioglitazone plus vildagliptin were found to be more effective in preserving -cell function, and in reducing insulin resistance, and inflammatory state parameters.

KW - -cell

KW - glimepiride

KW - inflammatory state

KW - insulin resistance

KW - pioglitazone

KW - vildagliptin

UR - http://www.scopus.com/inward/record.url?scp=77955020170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955020170&partnerID=8YFLogxK

U2 - 10.1055/s-0030-1255036

DO - 10.1055/s-0030-1255036

M3 - Article

VL - 42

SP - 663

EP - 669

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 9

ER -